Menu
No results found.
Weekly Share Price & Valuation Overview
Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States. The company's products include SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2; developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. It develops theranostic therapy and imaging products for the treatment of cancer in children and adults. The company was incorporated in 2010 and is based in Sydney, Australia.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Negative free cash flow — operations may rely on external financing.
- Market Cap Total equity value of the company (share price × shares outstanding).
- AUD 1.36B
- Enterprise Value Operating value: market cap + total debt − cash.
- AUD 1.06B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- AUD 10.78M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- AUD 0.04
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -0.16
- Shares Outstanding
- 371.93M
- Float Shares
- 236.57M
- Implied Shares Outstanding
- 371.93M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-6.35%
- Gross Margin (TTM) Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
100.00%
- ROA Return on assets: net income ÷ total assets.
-
-36.11%
- ROE Return on equity: net income ÷ shareholder equity.
-
-53.99%
- Revenue Growth Year-over-year revenue growth.
-
-13.50%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 13.74
- Total Cash Cash and equivalents.
- AUD 111.19M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- AUD -111.19M
- EBITDA & EBITDA margin suppressed (implausible vs revenue or not meaningful for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.